Pharma outsourcing is a drug or biotech company contracting specialist firms for work it does not keep in house, such as clinical research through a CRO, development and manufacturing through a CDMO, or field sales through a contract sales organization. ECG builds the outbound unit for the firms on the selling side of that market.
SOLUTION
Lead generation and outbound business development for biotech and pharma services
Enquirer Consulting Group (ECG) designs, staffs and runs a complete outbound sales unit for biotech companies and pharma services businesses, including CROs, CDMOs and specialty commercial services firms, proves it in market in four months, then hands it over. It opens peer-level conversations with the sponsors who award the work and routes every interested reply to your business development lead.
WHO BUYS
Who buys from a biotech, CDMO or CRO company, and how do you reach them?
Your buyers are a small, named set of people at sponsor companies. You reach them with a researched account list, a message tied to their program, and replies routed to your BD lead the same day. The roles depend on what you sell:
- CROs. Clinical operations, clinical outsourcing and vendor management leaders at biotech and pharma sponsors.
- CDMOs. CMC, process development, external manufacturing and quality leaders.
- Biotech platforms and research tools. Business development, search and evaluation, and R&D leaders at larger pharma and biotech companies.
- Specialty and commercial services. Commercial, market access and launch leaders at companies bringing a product to market.
These buyers choose a partner, not a product. Federal regulations define a contract research organization as a firm that takes on one or more of a sponsor's obligations, and FDA guidance describes how a drug owner and its contract manufacturer document who does what in a quality agreement. Quality and procurement can both weigh in. Outreach here has to read like a peer who knows the program, never like a blast.
We build the list account first: sponsors whose programs, stage or recent financing match what you do, then the named roles inside them, using public signals such as trial registrations, financing news and hiring.
WHERE IT STALLS
Why do conferences and inbound stall for pharma services pipelines?
Both wait for the buyer to come to you. A partnering meeting or trade show fills a few weeks with conversations, then the pipeline goes quiet until the next one. An inbound request for proposal arrives once a sponsor has decided to outsource, and if it is the first time they hear your name, you are bidding against firms they already knew.
If your BD team is a few senior people with strong networks, their weeks go to proposals, bid defenses and existing accounts. New-logo prospecting happens in the gaps, and the network never reaches the sponsor who has not met you.
The weak point is reach, not credibility. Your science and your references win the work once you are in the room. What is missing is a system that gets you into more rooms, on a schedule you control.
WHAT WE BUILD
What does ECG build for a biotech or pharma services BD team?
Five disciplines fix the reach problem. We add others, such as web or sector PR, only when your weak points call for them.
- Market and dataTarget sponsors by program, stage and service fit, the named roles inside each, and verified business contact data.
- MessagingSequences written for one scientific or commercial buyer, built on your approved claims and reviewed by your team before anything sends.
- Outbound engineCold email from separate warmed domains plus LinkedIn outreach, run by Enquirer AI. Your corporate domain never sends cold.
- Reply routingInterested replies reach your BD lead the same day with the account context attached, logged in your CRM.
- Operator and reportingA dedicated operator runs the unit day to day, with one live view of conversations, meetings and pipeline.
OUTSOURCE OR HIRE
Outsourced business development or an in-house BD hire: which fits your stage?
Hire in-house when a working outbound system already exists and you need more hands to run it. Outsource the build when the system is missing, because a new BD hire without one spends most of the week prospecting by hand instead of selling.
Build, Run, Own covers both ends: outsourced speed while we build and run the unit, and an in-house function at the end, because the system and the operator transfer to your team. The full trade-off is in our guide to outsourcing sales operations versus building an in-house team. For the outsourced SDR route, see how to hire an outsourced SDR team for medical devices.
THE DIFFERENCE
How is this different from a contract sales organization?
A contract sales organization supplies sales reps, typically field reps calling on healthcare professionals to promote a product. ECG does a different job. We build a business-to-business outbound unit that reaches the companies that buy your services or partner on your science, run it, and hand it to your team.
We do not promote drugs to prescribers or to any other healthcare professional. Our guide to contract sales organizations versus building your own team sets out when each fits.
THE FOUR MONTHS
What does the outbound unit look like in its first four months?
Months one and two build the unit, months two to four run it live in your market, and after month four your team runs it.
- Build, months one and two. We map target sponsors and roles, build and verify the data, write messaging from your approved claims for your team to review, stand up warmed sending domains and staff the operator.
- Run, months two to four. The unit goes live. First conversations typically land in the first weeks, because capacity comes from warmed assets rather than a cold start. Replies reach your BD lead the same day, and we report weekly against your baseline.
- Own, after month four. Your team runs the unit. A managed service is there if you would rather we keep operating it, but it is optional.
WHAT YOU OWN
What does your BD team own at the end?
Everything the unit runs on, set up in your name: the sending domains and mailboxes, the account lists and verified data, the messaging and sequences, the CRM records and dashboards, the documented playbook, and the trained GTM operator, who moves onto your team at handover. The Build, Run, Own page sets out how the handover works.
WHO IT IS FOR
Which biotech and pharma services companies is this for?
US biotech and pharma services companies with a real service or platform, real revenue, and a small BD team whose new business still rides on conferences, the founders' network and inbound requests. One senior person should own the growth decision.
If you make and sell the drug itself, see outbound sales engines for pharmaceutical companies. Earlier stage? Read our guide to building an outbound sales engine for a pharma startup. Diagnostics companies and labs have their own page: outbound sales for diagnostics and clinical labs.
Our named references are US medical. Tim Rath of Innovative Radiology and Paul Smaldone of Innovative Medical tell their stories on camera on our resources page.
FAQ
Frequently asked questions.
No. ECG builds business-to-business outbound. The engine reaches decision makers at sponsors and partners, runs on business contact data, never patient data, and every message is built on your approved claims and reviewed before it sends.
First conversations typically land in the first weeks of going live, because the unit runs on warmed assets rather than a cold start. Awarded work takes longer, since sponsors decide at the pace of their programs. Inside the four months we report qualified conversations and meetings, each metric defined up front, and we never promise awarded work on a timeline.
It depends on the scope, which your weak points set. The structure is a fixed four-month engagement to build and run the unit. After handover the running cost is yours, one operator plus tooling, or an optional managed service. Pricing is presented live on a call, scoped to your weak points.
AI handles part of it well: researching accounts and roles, and drafting at scale. Enquirer AI, our outbound engine, does that work. It does not decide which claims are safe to make, so a person reviews every message against your approved claims before it sends, and a person takes every interested reply.
See which sponsors your outbound could reach.
Tell us how your business development runs today. We come back with a free Reachable Buyer Map: which channels you run, which are idle, and what we would build first. No obligation, and we'll walk you through it if that's useful.
Get your free Reachable Buyer MapOr see the full solutions stack.